MX2019002321A - Identificación de mutaciones en variantes de opsina de canal con sensibilidad a la luz mejorada y métodos de uso de estas. - Google Patents
Identificación de mutaciones en variantes de opsina de canal con sensibilidad a la luz mejorada y métodos de uso de estas.Info
- Publication number
- MX2019002321A MX2019002321A MX2019002321A MX2019002321A MX2019002321A MX 2019002321 A MX2019002321 A MX 2019002321A MX 2019002321 A MX2019002321 A MX 2019002321A MX 2019002321 A MX2019002321 A MX 2019002321A MX 2019002321 A MX2019002321 A MX 2019002321A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- mutations
- identification
- light
- improved sensitivity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380871P | 2016-08-29 | 2016-08-29 | |
| PCT/US2017/049158 WO2018044912A1 (en) | 2016-08-29 | 2017-08-29 | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019002321A true MX2019002321A (es) | 2019-10-21 |
Family
ID=59859616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002321A MX2019002321A (es) | 2016-08-29 | 2017-08-29 | Identificación de mutaciones en variantes de opsina de canal con sensibilidad a la luz mejorada y métodos de uso de estas. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11041004B2 (https=) |
| EP (1) | EP3504227A1 (https=) |
| JP (1) | JP7116884B2 (https=) |
| KR (3) | KR102609571B1 (https=) |
| CN (2) | CN110023327B (https=) |
| AU (4) | AU2017319306B2 (https=) |
| BR (1) | BR112019003950A2 (https=) |
| CA (1) | CA3034887A1 (https=) |
| IL (2) | IL265010B2 (https=) |
| MX (1) | MX2019002321A (https=) |
| MY (1) | MY197491A (https=) |
| NZ (1) | NZ751983A (https=) |
| RU (1) | RU2019109021A (https=) |
| SG (2) | SG10202102061SA (https=) |
| WO (1) | WO2018044912A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3504227A1 (en) | 2016-08-29 | 2019-07-03 | Wayne State University | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof |
| CN113173984B (zh) | 2021-04-12 | 2022-08-30 | 中眸医疗科技(武汉)有限公司 | 一种新型光敏感通道蛋白vr1.0在制备视网膜感光细胞退行性疾病药物中的应用 |
| MX2024007770A (es) * | 2021-12-20 | 2024-07-01 | Genans Biotechnology Co Ltd | Restauracion visual optogenetica utilizando neuropsina acoplada a gq sensible a la luz (opsin 5). |
| EP4665750A1 (en) | 2023-02-17 | 2025-12-24 | Ray Therapeutics, Inc. | Gene therapy compositions and methods for treating diseases of the retina |
| WO2025137649A1 (en) * | 2023-12-22 | 2025-06-26 | Wayne State University | Method of enhancing viral mediated gene delivery |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| IE913929A1 (en) | 1990-11-13 | 1992-05-20 | Immunex Corp | Bifunctional selectable fusion genes |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| EP1919497B1 (en) | 2005-07-22 | 2020-02-12 | The Board of Trustees of the Leland Stanford Junior University | Light-activated cation channel and uses thereof |
| CN101484005A (zh) | 2006-05-04 | 2009-07-15 | 韦恩州立大学 | 通过向体内递送视紫红质核酸恢复视觉响应 |
| KR100922422B1 (ko) | 2006-06-27 | 2009-10-16 | 가부시키가이샤 어드밴테스트 | 반도체 시험 장치 및 반도체 메모리의 시험 방법 |
| WO2011140279A1 (en) | 2010-05-04 | 2011-11-10 | Wayne State University | Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells |
| KR101945962B1 (ko) | 2010-09-08 | 2019-02-08 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | 돌연변이 채널로돕신 2 |
| CN105755044A (zh) | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| WO2013071231A1 (en) * | 2011-11-12 | 2013-05-16 | Massachusetts Institute Of Technology | Channelrhodopsins for optical control of cells |
| CA2866405A1 (en) * | 2012-03-05 | 2013-09-12 | Wayne State University | Identification of channelopsin-2 (chop2) mutations and methods of use |
| EP2968476B1 (en) * | 2013-03-14 | 2021-05-05 | Wayne State University | A plasmin for use in enhancing delivery of therapeutic compounds to the eyes or for improving vision |
| EP3102290A1 (en) * | 2014-02-07 | 2016-12-14 | Massachusetts Institute Of Technology | Blue light-activated ion channel molecules and uses thereof |
| EP4678754A3 (en) | 2014-03-11 | 2026-04-08 | Wayne State University | A modified mglur6 promoter and methods of use |
| WO2015161308A1 (en) | 2014-04-18 | 2015-10-22 | Massachusetts Institute Of Technology | Mutant channelrhodopsins with altered ion selectivity |
| WO2016179038A1 (en) | 2015-05-01 | 2016-11-10 | Spark Therapeutics, Inc. | ADENO-ASSOCIATED VIRUS-MEDIATED CRISPR-Cas9 TREATMENT OF OCULAR DISEASE |
| LT3436051T (lt) | 2016-03-31 | 2021-11-25 | Spark Therapeutics, Inc. | Kolonėlėmis pagrįstas visiškai keičiamo masto raav gavimo būdas |
| WO2017210664A1 (en) | 2016-06-03 | 2017-12-07 | Massachusetts Institute Of Technology | Somatic opsins for single cell resolution optogenetics |
| AU2017302013B2 (en) | 2016-07-29 | 2022-05-26 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| EP3504227A1 (en) | 2016-08-29 | 2019-07-03 | Wayne State University | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof |
-
2017
- 2017-08-29 EP EP17767952.9A patent/EP3504227A1/en active Pending
- 2017-08-29 SG SG10202102061SA patent/SG10202102061SA/en unknown
- 2017-08-29 MX MX2019002321A patent/MX2019002321A/es unknown
- 2017-08-29 CN CN201780060143.3A patent/CN110023327B/zh active Active
- 2017-08-29 AU AU2017319306A patent/AU2017319306B2/en active Active
- 2017-08-29 KR KR1020197008895A patent/KR102609571B1/ko active Active
- 2017-08-29 MY MYPI2019001044A patent/MY197491A/en unknown
- 2017-08-29 IL IL265010A patent/IL265010B2/en unknown
- 2017-08-29 JP JP2019531572A patent/JP7116884B2/ja active Active
- 2017-08-29 SG SG11201901697QA patent/SG11201901697QA/en unknown
- 2017-08-29 RU RU2019109021A patent/RU2019109021A/ru unknown
- 2017-08-29 CA CA3034887A patent/CA3034887A1/en active Pending
- 2017-08-29 WO PCT/US2017/049158 patent/WO2018044912A1/en not_active Ceased
- 2017-08-29 KR KR1020237041296A patent/KR102877327B1/ko active Active
- 2017-08-29 IL IL310142A patent/IL310142A/en unknown
- 2017-08-29 US US16/328,916 patent/US11041004B2/en active Active
- 2017-08-29 KR KR1020257035361A patent/KR20250159068A/ko active Pending
- 2017-08-29 CN CN202410173021.7A patent/CN119979612A/zh active Pending
- 2017-08-29 NZ NZ751983A patent/NZ751983A/en unknown
- 2017-08-29 BR BR112019003950-3A patent/BR112019003950A2/pt unknown
-
2021
- 2021-05-19 US US17/324,501 patent/US12234267B2/en active Active
-
2022
- 2022-02-25 AU AU2022201291A patent/AU2022201291B2/en active Active
-
2024
- 2024-01-02 AU AU2024200016A patent/AU2024200016B9/en active Active
-
2025
- 2025-01-16 US US19/025,068 patent/US20250163111A1/en active Pending
- 2025-10-13 AU AU2025248765A patent/AU2025248765A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019002321A (es) | Identificación de mutaciones en variantes de opsina de canal con sensibilidad a la luz mejorada y métodos de uso de estas. | |
| DOP2018000245A (es) | Proteinas de fusion gdf15 y usos de estas | |
| CL2023001338A1 (es) | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. | |
| CL2020002161A1 (es) | Composiciones y métodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano. | |
| CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
| CO2020009402A2 (es) | Proteínas de fusión fc il-22 y métodos de uso | |
| PE20190563A1 (es) | Genes de mini-distrofina optimizados y casetes de expresion y su uso | |
| MX2023010757A (es) | Variantes de proteasa y sus usos. | |
| MX2020010881A (es) | Construcciones de anticuerpos anti-ror. | |
| CR20110245A (es) | Mutantes fgf21 y uso de los mismos. | |
| MX2014010664A (es) | Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso. | |
| MX385926B (es) | Proteínas de fusión de citoquinas. | |
| CL2020002597A1 (es) | Métodos para preparar composiciones proteicas estables | |
| AR121390A1 (es) | Composiciones y métodos para tratar la deficiencia auditiva no relacionada con la edad en un sujeto humano | |
| MX2017016610A (es) | Metodos de reduccion de olor. | |
| MX2021004925A (es) | Variantes de adn-polimerasa modificadas. | |
| CO2021010786A2 (es) | Toxinas apxia, apxiia y apxiiia inactivadas | |
| CL2020002650A1 (es) | Enzimas quinureninasa humanas y sus usos | |
| CL2023000491A1 (es) | Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020). | |
| CU20210008A7 (es) | Aspirasas solubilizadas | |
| DOP2025000286A (es) | Composiciones para tratae la pérdida de audición y/o la pérdida de visión asociada a clrn1 | |
| EA201991768A1 (ru) | Слитые белки на основе фактора ix и способы их получения и пути применения | |
| BR112022011831A2 (pt) | Molécula de grelina acilada, composição, uso de uma molécula de grelina acilada e kit de partes | |
| PE20211235A1 (es) | Variantes de lfa3 y composiciones y usos de las mismas | |
| BR112023023794A2 (pt) | Sequências de proteínas e ácidos nucleicos para vacinas covid-19 |